Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   AR Bank Custom set (Custom)
AR Bank # 0011 Escherichia coli
Study ID: BIT-11

Biosample Accession #: SAMN04014852
MLST: 2(Pasteur), 167(Achtman)

Panel:  Enterobacterales Carbapenem Breakpoint (BIT)  |  GN7F ARLN (Custom)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 8I
Ampicillin >32R
Ampicillin/sulbactam 132R
Aztreonam >64R
Aztreonam/avibactam 10.06S
Cefazolin >8R
Cefepime >32R
Cefepime/zidebactam 20.25---
Cefotaxime >128R
Cefotaxime/clavulanic acid 1<=0.5---
Cefoxitin 16I
Ceftazidime 128R
Ceftazidime/avibactam 1<=0.5S
Ceftazidime/clavulanic acid 11---
Ceftolozane/tazobactam 11S
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 50.5I
Doripenem <=0.12S
Eravacycline 30.06S
Ertapenem 0.25S
Gentamicin >16R
Imipenem <=0.5S
Imipenem/relebactam 10.12S
Imipenem+chelators 4<=0.25---
Levofloxacin >8R
Meropenem <=0.12S
Meropenem-vaborbactam 1<=0.5S
Nitrofurantoin 32S
Piperacillin/tazobactam 18S
Plazomicin 0.25S
Tetracycline >32R
Tigecycline 3<=0.5S
Tobramycin >16R
Trimethoprim/sulfamethoxazole 1>8R
S – I –R Interpretation (INT) derived from CLSI 2025 M100 S35
1 Reflects MIC of first component
2 Cefepime to zidebactam ratio (1:1)
3 Based on FDA break points
4 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
5 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(3)-IIa, aac(6')-Ib-cr, aph(6)-Id, strA
Beta-lactam CTX-M-15, OXA-1
Efflux pumps/Other ACRF, EMRD
Macrolide-Lincosamide-Streptogramin MDF(A)
Phenicols/Bicyclomycins catB4
Sulfonamides sul2
Tetracyclines tet(A), tet(R)
Trimethoprim dfrA4
 
Disclaimer:
No disclaimer.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.



Disclaimer:

Isolate History
Date Action Performed
03/07/25INT was updated with a new value for Aztreonam/avibactam: from '---' to 'S'
04/20/23MIC was updated with a new value for Eravacycline: from '0.12' to '0.06'
04/10/23INT was updated with a new value for Amikacin: from 'R' to 'I'
04/10/23INT was updated with a new value for Amikacin: from 'S' to 'R'
Top of Page
TOP